Concepedia

Robert Croop

RC

Statistics

Publications

39

Citations

2.7K

H-Index

22

Active since

1995

Affiliations

Biohaven Pharmaceuticals (United States)(Current)

Albert Einstein College of Medicine

Pfizer (United States)

Certara (United States)

Bristol-Myers Squibb (United States)

Robert Croop is an author at Biohaven Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and pharmacology.

ORCID

Top concepts

Publications per year

1995–2024

39

Publications

39

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 379 citations

, , +5

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, Robert Croop, Elyse Stock et al. · New England Journal of Medicine · 2019 · 379 citations · Full text

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B. Lipton, David Kudrow et al. · The Lancet · 2020 · 334 citations

, , +7

The Safety Profile of Naltrexone in the Treatment of Alcoholism

Robert Croop · Archives of General Psychiatry · 1997 · 214 citations

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

Richard B. Lipton, Robert Croop, David Stock et al. · The Lancet Neurology · 2023 · 136 citations

, , +4

1–5 of 39